Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line

Clin Cancer Res. 2002 Jan;8(1):287-92.

Abstract

7-ethyl-10-[4-(1-piperidyl)-1-piperidyl] carbonyloxy-camptothecin, a topoisomerase I (topo I) inhibitor, is one of the most active agent against lung cancer, and its radiosensitizing effect has been reported recently. We evaluated a combination in vitro effect of irradiation and 7-ethyl-10-hydroxy-CPT (SN-38), an active metabolite of 7-ethyl-10-[4- (1-piperidyl)-1-piperidyl] carbonyloxy-camptothecin, on a human small cell lung cancer cell line (SBC-3) and its cisplatin-resistant subline (SBC-3/CDDP). Growth-inhibitory effects of irradiation with or without SN-38 were determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. A modified isobologram method was used to evaluate the treatment interaction. The combination of irradiation and SN-38 showed a synergistic inhibitory effect on the growth of SBC-3/CDDP despite its cross-resistance to irradiation and SN-38. In contrast, the same combination showed only an additive effect on the growth of parental SBC-3 cells. There was no significant difference in topo I protein expression between these two cell lines. In SBC-3 cells, topo I catalytic activity was suppressed by 4 Gy of irradiation, without a decrease of nuclear topo I protein, whereas the exposure of SBC-3 cells to 1 microM SN-38 subsequent to irradiation showed no remarkable additional effects on both topo I activity and protein content. On the other hand, in SBC-3/CDDP cells, topo I activity was unchanged by irradiation, but the subsequent exposure to SN-38 gave rise to a decrease in topo I activity, which was accompanied by a significant decrease in the topo I protein content (P = 0.02). These observations may indicate that SN-38 induces sequestration of topo I onto DNA in radiation-treated SBC-3/CDDP cells and suggest that the synergistic effect of irradiation and SN-38 in SBC-3/CDDP cells was considered attributable to DNA repair-related enhanced recruitment of topo I onto the damaged DNA.

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Camptothecin / analogs & derivatives
  • Camptothecin / therapeutic use*
  • Carcinoma, Small Cell / enzymology
  • Carcinoma, Small Cell / pathology
  • Carcinoma, Small Cell / therapy*
  • Cell Survival / drug effects
  • Cell Survival / radiation effects
  • Cisplatin / therapeutic use*
  • Combined Modality Therapy
  • DNA Topoisomerases, Type I / metabolism
  • Drug Resistance, Neoplasm*
  • Drug Synergism
  • Enzyme Inhibitors / therapeutic use*
  • Formazans
  • Humans
  • Immunoblotting
  • Irinotecan
  • Lung Neoplasms / enzymology
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy*
  • Tetrazolium Salts
  • Topoisomerase I Inhibitors*
  • Tumor Cells, Cultured / drug effects
  • Tumor Cells, Cultured / radiation effects*

Substances

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Formazans
  • Tetrazolium Salts
  • Topoisomerase I Inhibitors
  • MTT formazan
  • Irinotecan
  • DNA Topoisomerases, Type I
  • Cisplatin
  • Camptothecin